10x Genomics, Inc. TXG Instruments — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s instruments — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s instruments — revenue?
- 10x Genomics, Inc. (TXG) reported instruments — revenue of $11.26M in Q1 2026.
- How has 10x Genomics, Inc.'s instruments — revenue changed year-over-year?
- 10x Genomics, Inc.'s instruments — revenue decreased by 24.0% year-over-year, from $14.82M to $11.26M.
- What is the long-term trend for 10x Genomics, Inc.'s instruments — revenue?
- Over 4 years (2021 to 2025), 10x Genomics, Inc.'s instruments — revenue has grown at a -3.1% compound annual growth rate (CAGR), from $64.47M to $56.78M.
- What does instruments — revenue mean?
- This metric represents the total gross revenue generated from the sale of hardware and instrumentation platforms within the company's product portfolio. It serves as a key indicator of the company's installed base growth and market penetration for its primary technology systems. Tracking this revenue stream helps investors assess the adoption rate of the company's core analytical hardware among research and clinical customers.